Philippe C. Bishop, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutics

FOSTER CITY, Calif.--(BUSINESS WIRE)--Dec. 15, 2014-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Philippe C. Bishop, MD, will join the company as Senior Vice President, Hematology and Oncology Therapeutics. In this position, Dr. Bishop will report to John McHutchison, MD, Executive Vice President, Clinical Research and will have responsibility for Gilead’s programs in oncology. Dr. Bishop will also join Gilead’s Executive Committee.

“Philippe is an accomplished physician with an extensive background in cancer drug development and I am very pleased to welcome him to Gilead,” said Dr. McHutchison. “Philippe’s appointment reflects Gilead’s ongoing commitment to further building a leading hematology and oncology therapeutic area. His clinical development expertise, translational focus and strategic leadership will be of great value as we work to advance our growing pipeline of therapies for hematological malignancies and solid tumors.”

Dr. Bishop joins Gilead from Genentech, where he has served as Vice President, Product Development, Oncology since 2007. At Genentech, he was responsible for the development of Avastin, contributed to many of the company’s oncology pipeline therapeutics and was a member of the Roche/Genentech joint leadership team. Prior to joining Genentech, Dr. Bishop led efforts to develop cancer therapies at Johnson & Johnson and Sanofi-Aventis. Dr. Bishop also previously held positions at the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH).

“Over the last several years, Gilead has worked to build strong expertise and an extensive pipeline within the hematology and oncology areas,” said Dr. Bishop. “I am excited to join this dedicated, scientifically focused team, which shares my commitment and passion for scientific innovation, and I look forward to working with them to bring new therapeutic options to people living with cancer.”

Dr. Bishop received his undergraduate degree from Loyola Marymount University in Los Angeles and his medical degree from the University of Nevada School of Medicine. He completed training in internal medicine at the University of Washington School of Medicine and a medical oncology fellowship at the National Cancer Institute (NCI).

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Source: Gilead Sciences, Inc.

Gilead Sciences, Inc.
Patrick O’Brien, 650-522-1936 (Investors)
Amy Flood, 650-522-5643 (Media)